

Dear CBA members,

As China entering its 12th Five Year plan, a new era of BioPharma in China is also coming. At this historic time of point, TBI would like to dedicate a special issue to discuss the future of China BioPharma industry.

We would like to invite you to submit an article on following subjects and any other issues that you feel strongly and with personal experiences.

The major topics are:

1. What is your assessment of current status of China's biopharm? How does that compare with biopharm in US and ROW?
2. What China can learn from the success and failure of biopharm in US and ROW from the past 20-30 years?
3. What China may do better in this field? a "bipharma with Chinese characteristics"?
4. What are the areas in biopharm that China should be focusing in the near future? and how?
5. What are the major huddles (scientific, technical, financial, regulatory) that China has now?
6. What Government can and should do better?
7. What "sea turtle" can do better? any lesson can be drawn from the past, considering over 90% of them were "failed"?
8. What you can share with us from your own experience and a "sea turtle" entrepreneur?
9. What is you vision for the biopharma industry in China in 5-10 years?
10. How basic research in biopharma can be improved and how that would impact at china's bipharma future?

You are welcome to address these issues and other issues you consider important from a broad perspective or from a unique angle. We would like to ask you to be bold, advocative, creative and at the same be constructive and positive.

Please send your contribution to editor@tbiweb.org alone with a short Bio (9150 words) and a recent high resolution photo (in a separate jpg file)

We look forward to publishing your thoughts and suggestions.

John Wang
Editor-in-Chief